These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31324847)

  • 1. The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome.
    Fodor J; Riley BT; Kass I; Buckle AM; Borg NA
    Sci Rep; 2019 Jul; 9(1):10523. PubMed ID: 31324847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.
    Naisbitt DJ; Yang EL; Alhaidari M; Berry NG; Lawrenson AS; Farrell J; Martin P; Strebel K; Owen A; Pye M; French NS; Clarke SE; O'Neill PM; Park BK
    AIDS; 2015 Nov; 29(18):2385-95. PubMed ID: 26372480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.
    Norcross MA; Luo S; Lu L; Boyne MT; Gomarteli M; Rennels AD; Woodcock J; Margulies DH; McMurtrey C; Vernon S; Hildebrand WH; Buchli R
    AIDS; 2012 Jul; 26(11):F21-9. PubMed ID: 22617051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.
    Illing PT; Vivian JP; Dudek NL; Kostenko L; Chen Z; Bharadwaj M; Miles JJ; Kjer-Nielsen L; Gras S; Williamson NA; Burrows SR; Purcell AW; Rossjohn J; McCluskey J
    Nature; 2012 Jun; 486(7404):554-8. PubMed ID: 22722860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
    Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
    Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.
    Chessman D; Kostenko L; Lethborg T; Purcell AW; Williamson NA; Chen Z; Kjer-Nielsen L; Mifsud NA; Tait BD; Holdsworth R; Almeida CA; Nolan D; Macdonald WA; Archbold JK; Kellerher AD; Marriott D; Mallal S; Bharadwaj M; Rossjohn J; McCluskey J
    Immunity; 2008 Jun; 28(6):822-32. PubMed ID: 18549801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire.
    Illing PT; van Hateren A; Darley R; Croft NP; Mifsud NA; King S; Kostenko L; Bharadwaj M; McCluskey J; Elliott T; Purcell AW
    Front Immunol; 2021; 12():672737. PubMed ID: 34093574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.
    Llano A; Brander C
    Cell Res; 2012 Dec; 22(12):1637-9. PubMed ID: 22777424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
    Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T
    Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients.
    Faridi RM; Patel S; Dharmani-Khan P; Gill J; Berka N; Khan FM
    Microbiol Immunol; 2020 Mar; 64(3):210-218. PubMed ID: 31876322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide binding specificities of HLA-B*5701 and B*5801.
    Zhang Y; Mei H; Wang Q; Xie J; Lv J; Pan X; Tan W
    Sci China Life Sci; 2012 Sep; 55(9):818-25. PubMed ID: 23015131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.